The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.
Last week, FDA granted accelerated approval to Replimune Group Inc. for it’s biologic, RP1 (vusolimogene oderparepvec), following the FDA Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
